<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:department>MRC Human Genetics Unit</gtr:department><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/AD8CF3B1-4CF3-4A74-A9BA-04D08881165A"><gtr:id>AD8CF3B1-4CF3-4A74-A9BA-04D08881165A</gtr:id><gtr:firstName>Joseph Arthur</gtr:firstName><gtr:surname>Marsh</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FM02122X%2F1"><gtr:id>AF5EF196-8A74-4F11-9B17-3DDAFAC4CCD5</gtr:id><gtr:title>Protein Complexes and Human Genetic Disease</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>MR/M02122X/1</gtr:grantReference><gtr:abstractText>Many human diseases are caused by genetics -- that is, the genes that you inherited from your parents. Slight variations between the genes of different people can have wide-ranging effects. Understanding how this genetic variation contributes to disease is of huge importance for disease prevention, diagnosis and treatment. While much progress has been made in recent years, aided by the ability to sequence genes and genomes at much lower cost, there is still much we do not understand about how differences between genes can cause disease.

Most genes can be thought of quite simply as a set of instructions on how to build a protein. These are called &amp;quot;protein-coding&amp;quot; genes. Genetic changes in protein-coding genes can modify these instructions, thus affecting the protein, either by changing its structure, or by causing more or less to be made. Therefore, one thing that has been quite useful for understanding genetic disease is to consider how proteins will be affected. Genetic variations that cause large changes to proteins are much more likely to cause disease.

One aspect of this that has been often ignored is the fact that most proteins do not exist in isolation. Instead, many proteins can bind to other proteins and form &amp;quot;protein complexes&amp;quot;. Such protein complexes are fundamental to nearly all biological processes. A major focus of my past research was on trying to understand how proteins assemble into complexes. In the current research proposal, I aim to build upon this, and to study how protein complexes are related to human genetic disease. Specifically, I believe that a genetic change is more likely to cause a disease if it affects a protein that assembles into a complex, and that this will depend upon the type of complex that is formed. In fact, early results I present in this proposal strongly suggest this to be true.

The ultimate aim of this research will be to develop improved methods for predicting whether genetic changes are likely to cause disease. Such methods exist now, but they don't use information on protein complexes. By incorporating the knowledge of protein complexes that will be obtained from this project, we should be able to substantially improve upon existing predictions.

The benefits of improved predictions are great. In particular, they will significantly enhance our ability to identify specific genetic changes that cause diseases or affect other human traits. Furthermore, they could be used in a clinical setting, to predict from a person's genes whether they are likely to get a specific disease, or to diagnose whether their symptoms could be caused by a genetic disorder.</gtr:abstractText><gtr:technicalSummary>Many human diseases have a significant genetic component, and so understanding how genetic variation translates into observable phenotypic differences is of tremendous importance for disease prevention, diagnosis and treatment. While consideration of protein structural context has often been useful for explaining and predicting the effects of genetic variants, the fact that most proteins can assemble into complexes is often ignored. The main premise of this proposal, which is strongly supported by preliminary results presented here, is that the quaternary structural context of a mutation will often have a big influence on its phenotype, in ways that have not previously been recognised. Therefore, I propose to use computational approaches to study human genetic variation (both coding and non-coding) from the perspective of protein complexes, taking advantage of the huge amounts of protein structure and gene sequence data now available. Specifically, we will investigate how the position of a mutation within a complex affects its likelihood of having a large phenotypic impact. We will also study how the overall type of quaternary structure formed is related to its dominant or recessive mode of inheritance. Furthermore, we will use simulations to assess how the order of protein complex assembly pathways can influence the effects of genetic variants. Finally, we will build upon the results of these analyses to develop new methods for predicting the phenotypic impacts of mutations, with ultimate the aim of facilitating the prioritisation and identification of causal variants</gtr:technicalSummary><gtr:potentialImpactText>Beyond the important basic science impacts of this proposed research described in the &amp;quot;Academic Beneficiaries&amp;quot; section, there will be other beneficiaries.

Ultimately, it is hoped that this research will improve our understanding of genetic disease in a way that will have a positive benefit for human health. This can happen if the methods we develop are shown to be useful for predicting phenotypic impacts, or if others develop new tools that incorporate our findings. Specifically, the ability to prioritise variants that are more likely to have a large phenotypic effect can reduce the sample size needed to identify a given association, or increase the statistical power to identify an association from a given dataset. Therefore, if this project is successful, more genetic associations could be identified for less cost. Even if the incorporation of protein complex information provides only a small improvement over existing methods, this would provide a tangible benefit when considering the large number of people required for these studies and the large number of variants to consider.

A further potential medical benefit of this research will come as sequencing drops in cost and enters more widespread clinical use. De novo mutations that have not previously been seen are increasingly being associated with human disorders, for example autism. However, just because we can identify de novo mutations, does not mean that they have any medically relevant consequences. Therefore, improved prioritisation of mutations that are more likely to have a phenotypic effect will be useful for disease diagnosis and choice of treatment, providing information on the likelihood that symptoms are caused by a given variant. Furthermore, this could improve predictions of the likelihood that a healthy person will later develop a genetic disease, which could be useful for disease prevention.

A secondary potential benefit of this work is in the field of drug discovery. Specifically, I hypothesise that the mutation-sensitive interfaces identified in Question 2 of the proposal could represent good potential drug targets. The reason is simple: weaker binding at an inhibition-sensitive interface can give equivalent inhibition of assembly compared to stronger binding at a less inhibition-sensitive interface. If the above analysis is successful, and there really is a significant correspondence between predicted inhibition sensitivity and mutation phenotype, this will be a strong indication that inhibition-sensitive interfaces could be prioritised as potential drug targets. This would facilitate targeting of specific interfaces within a complex for in silico screening, which could ultimately lead to more efficient experimental screening in either an academic or industrial setting.</gtr:potentialImpactText><gtr:fund><gtr:end>2020-06-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2015-07-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>922961</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs><gtr:softwareAndTechnicalProductOutput><gtr:description>This is a computational method we developed for predicting the ordered assembly pathways from the three-dimensional structures of protein complexes. While an earlier version of the method was described previously (Marsh et el., Cell 2013), this is an updated method and represents the first public release.</gtr:description><gtr:id>9E4DCEC5-51BF-437B-B2AD-B3C6062FF5AE</gtr:id><gtr:impact>This method enabled our recent publication &amp;quot;Operon gene order is optimized for ordered protein complex assembly&amp;quot; (Cell Reports, 2016), and is now freely available for anyone to use.</gtr:impact><gtr:outcomeId>56af7b2a508523.79094382</gtr:outcomeId><gtr:title>assembly-prediction</gtr:title><gtr:type>Software</gtr:type><gtr:url>https://github.com/marshlab/assembly-prediction</gtr:url><gtr:yearFirstProvided>2016</gtr:yearFirstProvided></gtr:softwareAndTechnicalProductOutput></gtr:softwareAndTechnicalProductOutputs><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>12AD8D2D-0F81-4AE5-B68A-C7E452D472D7</gtr:id><gtr:title>Operon Gene Order Is Optimized for Ordered Protein Complex Assembly.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/17130677726903d91237be8f28bc4c97"><gtr:id>17130677726903d91237be8f28bc4c97</gtr:id><gtr:otherNames>Wells JN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>56af770742fd49.57951169</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8AC796A0-821B-4BDA-95A9-771B69DB3772</gtr:id><gtr:title>Evolution of condensin and cohesin complexes driven by replacement of Kite by Hawk proteins.</gtr:title><gtr:parentPublicationTitle>Current biology : CB</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/17130677726903d91237be8f28bc4c97"><gtr:id>17130677726903d91237be8f28bc4c97</gtr:id><gtr:otherNames>Wells JN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0960-9822</gtr:issn><gtr:outcomeId>5898afe71c3013.79682245</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4DD34AC6-BE1A-4763-90E1-3DCC1F09842A</gtr:id><gtr:title>Novel pathogenic mutations in C1QTNF5 support a dominant negative disease mechanism in late-onset retinal degeneration.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/00907fb3dc7bf170333a9e928629f700"><gtr:id>00907fb3dc7bf170333a9e928629f700</gtr:id><gtr:otherNames>Stanton CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5a4cf27454ac26.36032446</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E5FE2C8D-5E63-4CE9-A0AE-B0DBF4889AF0</gtr:id><gtr:title>Cotranslational protein assembly imposes evolutionary constraints on homomeric proteins.</gtr:title><gtr:parentPublicationTitle>Nature structural &amp; molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2cb10fc9c59c4712409caddcf226407a"><gtr:id>2cb10fc9c59c4712409caddcf226407a</gtr:id><gtr:otherNames>Natan E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1545-9985</gtr:issn><gtr:outcomeId>5a93edbd6c0f30.76693779</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>64BF9CC7-7FA3-4EE9-9E25-F9740146770B</gtr:id><gtr:title>A Restricted Repertoire of De Novo Mutations in ITPR1 Cause Gillespie Syndrome with Evidence for Dominant-Negative Effect.</gtr:title><gtr:parentPublicationTitle>American journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d6a9f54b6d97bf813b9b92499f28820d"><gtr:id>d6a9f54b6d97bf813b9b92499f28820d</gtr:id><gtr:otherNames>McEntagart M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0002-9297</gtr:issn><gtr:outcomeId>585d7414ce4876.87186216</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>40E0DDB3-A64B-4957-919A-530AF2E2B40E</gtr:id><gtr:title>Regulation, evolution and consequences of cotranslational protein complex assembly.</gtr:title><gtr:parentPublicationTitle>Current opinion in structural biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2cb10fc9c59c4712409caddcf226407a"><gtr:id>2cb10fc9c59c4712409caddcf226407a</gtr:id><gtr:otherNames>Natan E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0959-440X</gtr:issn><gtr:outcomeId>5898afe77c7bf1.36183889</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CE295980-7A23-4E7A-86AC-E938EE9AD921</gtr:id><gtr:title>SMCHD1 mutations associated with a rare muscular dystrophy can also cause isolated arhinia and Bosma arhinia microphthalmia syndrome.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/977df90660e78bb470906ca51984d8c9"><gtr:id>977df90660e78bb470906ca51984d8c9</gtr:id><gtr:otherNames>Shaw ND</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>5898afe7451170.08206442</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A3CE6747-FA03-495A-9747-A6580CE18B05</gtr:id><gtr:title>Structural Determinants of Sleeping Beauty Transposase Activity.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f0dc15c16d80b4c60381b3d226b595b8"><gtr:id>f0dc15c16d80b4c60381b3d226b595b8</gtr:id><gtr:otherNames>Abrus?n G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn><gtr:outcomeId>585d7417d121e2.09089645</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>20E72D33-B674-4AF3-9825-A279C6CF678C</gtr:id><gtr:title>Functional determinants of protein assembly into homomeric complexes.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/70f6ad02eb78108abd4ea1c801bb299e"><gtr:id>70f6ad02eb78108abd4ea1c801bb299e</gtr:id><gtr:otherNames>Bergendahl LT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5a3b9578702c29.48484936</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AAAC63DE-969D-4F3B-8C43-CEFF75C39D99</gtr:id><gtr:title>Kinetic Analysis of Protein Stability Reveals Age-Dependent Degradation.</gtr:title><gtr:parentPublicationTitle>Cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cde5371a5342bd6efa4fc102d5563d00"><gtr:id>cde5371a5342bd6efa4fc102d5563d00</gtr:id><gtr:otherNames>McShane E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0092-8674</gtr:issn><gtr:outcomeId>5898afe7c3b455.86108078</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EC2FC9C0-0AD5-4756-A116-45B16B275E7D</gtr:id><gtr:title>ER stress-induced aggresome trafficking of HtrA1 protects against proteotoxicity.</gtr:title><gtr:parentPublicationTitle>Journal of molecular cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2f7f0b7bd64d0e0c2685c76531e87798"><gtr:id>2f7f0b7bd64d0e0c2685c76531e87798</gtr:id><gtr:otherNames>Gerhardt MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1759-4685</gtr:issn><gtr:outcomeId>5a93edbdd47e04.85082864</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8BAC46AE-4371-4D61-8BC1-987037CCF038</gtr:id><gtr:title>The genetic basis and evolution of red blood cell sickling in deer.</gtr:title><gtr:parentPublicationTitle>Nature ecology &amp; evolution</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03f3f2a4df788fca978b32ed5fd834f7"><gtr:id>03f3f2a4df788fca978b32ed5fd834f7</gtr:id><gtr:otherNames>Esin A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>2397-334X</gtr:issn><gtr:outcomeId>5a4cf4e7b3ba76.82078777</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>00CDD8EB-CE7A-45E3-BEF0-AFA2A14B6AD7</gtr:id><gtr:title>Signalling assemblies: the odds of symmetry.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/efa4d601837a858c2272f5162c5ddf97"><gtr:id>efa4d601837a858c2272f5162c5ddf97</gtr:id><gtr:otherNames>Maksay G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>5a3b948c720d99.96641470</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E3A25D22-4B4D-43A8-B888-110A39C74A2B</gtr:id><gtr:title>Alpha Helices Are More Robust to Mutations than Beta Strands.</gtr:title><gtr:parentPublicationTitle>PLoS computational biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f0dc15c16d80b4c60381b3d226b595b8"><gtr:id>f0dc15c16d80b4c60381b3d226b595b8</gtr:id><gtr:otherNames>Abrus?n G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1553-734X</gtr:issn><gtr:outcomeId>5898afe7a1b891.36455686</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>14A4C3D4-B63F-4CA4-9B54-3181A06D4F3F</gtr:id><gtr:title>Characterization of a novel RP2-OSTF1 interaction and its implication for actin remodelling.</gtr:title><gtr:parentPublicationTitle>Journal of cell science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/363ec37f7b6d17b109db41b4b22e6a14"><gtr:id>363ec37f7b6d17b109db41b4b22e6a14</gtr:id><gtr:otherNames>Lyraki R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0021-9533</gtr:issn><gtr:outcomeId>5a93edbdab5c53.31254312</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/M02122X/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>FB395309-E202-4FE8-87B0-041A3D72D4D4</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.5  Research design and methodologies (aetiology)</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>